Swiss pharmaceutical giant Roche said yesterday that it would acquire a majority of tumor-testing company Foundation Medicine for more than US$1 billion, in a deal aimed at improving both cancer treatment and drug development.
Foundation Medicine is the leader in the growing area of sequencing genes of tumor samples, looking for mutations that can help predict which drug would be most effective for a particular patient.
Roche, which is the world’s biggest seller of cancer drugs, said it would use some insights from that testing to develop drugs and better tailor them for specific groups of patients. In addition, Roche, which also has a huge diagnostics business, will sell Foundation Medicine’s tests outside the US.
“I think it just brings personalized healthcare in oncology to a new level,” Daniel O’Day, who runs Roche’s pharmaceutical business, said in an interview.
For its part, Foundation Medicine, which is based in Cambridge, Massachusetts, will get financial support and work with Roche on some new products. Roche will also help promote such testing to oncologists and pathologists in the US.
“We believe this approach will become the norm in oncology in the not-too-distant future, and this takes us another step in that direction,” Foundation Medicine chief executive Michael Pellini said in an interview.
Under the terms of the deal, Roche will invest US$250 million in Foundation Medicine by acquiring 5 million newly issued shares at US$50 a share, a 109 percent premium to Foundation’s closing price on Friday. Roche will also make a tender offer at the same price to acquire about 15.6 million shares.
In total, Roche would pay just over US$1 billion and end up with a stake of between 52.4 percent and 56.3 percent on a fully diluted basis, the companies said.
The transaction, which is subject to approval by Foundation Medicine’s shareholders, has been approved unanimously by Foundation’s board. Three venture capital companies holding a combined 31 percent of Foundation shares — Third Rock Ventures, Kleiner Perkins Caufield & Byers and Google Ventures — have agreed to vote for the transaction and to tender at least a majority of their shares.
Foundation Medicine’s main product, called FoundationOne, sequences more than 300 genes in a sample of a solid tumor, such as a lung or breast tumor. Often, a particular mutation indicates a tumor would be vulnerable to attack by a particular drug. A newer product, FoundationOne Heme, is for blood cancers.
Foundation Medicine, which went public in 2013, had US$61.1 million in revenue last year, up from US$29 million the year before. It performed more than 24,200 tests for patient treatment last year, up from only about 9,000 in 2013.
The company is still losing money, however.
Taiwan Transport and Storage Corp (TTS, 台灣通運倉儲) yesterday unveiled its first electric tractor unit — manufactured by Volvo Trucks — in a ceremony in Taipei, and said the unit would soon be used to transport cement produced by Taiwan Cement Corp (TCC, 台灣水泥). Both TTS and TCC belong to TCC International Holdings Ltd (台泥國際集團). With the electric tractor unit, the Taipei-based cement firm would become the first in Taiwan to use electric vehicles to transport construction materials. TTS chairman Koo Kung-yi (辜公怡), Volvo Trucks vice president of sales and marketing Johan Selven, TCC president Roman Cheng (程耀輝) and Taikoo Motors Group
Among the rows of vibrators, rubber torsos and leather harnesses at a Chinese sex toys exhibition in Shanghai this weekend, the beginnings of an artificial intelligence (AI)-driven shift in the industry quietly pulsed. China manufactures about 70 percent of the world’s sex toys, most of it the “hardware” on display at the fair — whether that be technicolor tentacled dildos or hyper-realistic personalized silicone dolls. Yet smart toys have been rising in popularity for some time. Many major European and US brands already offer tech-enhanced products that can enable long-distance love, monitor well-being and even bring people one step closer to
RECORD-BREAKING: TSMC’s net profit last quarter beat market expectations by expanding 8.9% and it was the best first-quarter profit in the chipmaker’s history Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), which counts Nvidia Corp as a key customer, yesterday said that artificial intelligence (AI) server chip revenue is set to more than double this year from last year amid rising demand. The chipmaker expects the growth momentum to continue in the next five years with an annual compound growth rate of 50 percent, TSMC chief executive officer C.C. Wei (魏哲家) told investors yesterday. By 2028, AI chips’ contribution to revenue would climb to about 20 percent from a percentage in the low teens, Wei said. “Almost all the AI innovators are working with TSMC to address the
FUTURE PLANS: Although the electric vehicle market is getting more competitive, Hon Hai would stick to its goal of seizing a 5 percent share globally, Young Liu said Hon Hai Precision Industry Co (鴻海精密), a major iPhone assembler and supplier of artificial intelligence (AI) servers powered by Nvidia Corp’s chips, yesterday said it has introduced a rotating chief executive structure as part of the company’s efforts to cultivate future leaders and to enhance corporate governance. The 50-year-old contract electronics maker reported sizable revenue of NT$6.16 trillion (US$189.67 billion) last year. Hon Hai, also known as Foxconn Technology Group (富士康科技集團), has been under the control of one man almost since its inception. A rotating CEO system is a rarity among Taiwanese businesses. Hon Hai has given leaders of the company’s six